# A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.

Source: https://onco.cc/trials/nct05970016/  
OnCo record `nct05970016` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TCC1727 tablet（1） in advanced solid tumours, run by Beijing Tide Pharmaceutical Co., Ltd, now recruiting.

## Summary

A Phase I/II Clinical Study in Patients with Advanced Solid Tumor. is a phase 1/2 interventional study registered as NCT05970016 by Beijing Tide Pharmaceutical Co., Ltd, with 56 participants planned, started 2023-08-07 and due to reach its primary completion in 2025-07-30. Interventions recorded: TCC1727 tablet（1） and TCC1727 tablet（2）.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05970016
- Phase: 1/2
- Setting: A Phase I/II Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TCC1727 Tablets in Patients with Advanced Solid Tumor.
- Sponsor: Beijing Tide Pharmaceutical Co., Ltd
- Enrolled: 56

## Sources

- ClinicalTrials.gov NCT05970016: https://clinicaltrials.gov/study/NCT05970016

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Beijing Tide Pharmaceutical](https://onco.cc/companies/beijing-tide-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct05970016.json